Please assess the completion status of the following clinical trial:

Trial Title: RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous~* Cervical length as measured on transvaginal examination \< 30mm between gestational ages of 16 weeks 0 days to 22 weeks 3 days~* Gestational age 16 weeks 3 days to 22 weeks 6 days at time of randomization~Exclusion Criteria:~* Multifetal gestation~* Progesterone treatment after 14 weeks 6 days during current pregnancy~* Vaginal bleeding, heavier than spotting, after 15 weeks 6 days~* Amniotic membranes prolapsed beyond external os~* Preterm rupture of membranes~* Fetal anomaly~* Pregnancy without a viable fetus~* Current or planned cervical cerclage~* Congenital Mullerian abnormality of the uterus~* Contraindication to intra-muscular injections~* Hypertension requiring medication~* Diabetes managed with insulin or oral hypoglycemic agents~* DES exposure~* Cervical surgery such as cold knife conization~* Planned indicated preterm delivery~* Participation in another interventional study that influences age at delivery~* Participation in this trial in a previous pregnancy~* Prenatal care or delivery planned outside a MFMU Network center

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 17 alpha-hydroxyprogesterone caproate (Type: ACTIVE_COMPARATOR): 250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oil given by weekly injection until 37 weeks gestation or delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).